10128 - Functional Imaging for Prostate Cancer: Therapeutic Implications

Course Directors

Carina Mari Aparici, M.D., University of California, San Francisco
Youngho Seo, Ph.D., University of California, San Francisco

Description

Functional radionuclide imaging modalities, now commonly combined with anatomical imaging modalities CT or MRI (SPECT/CT, PET/CT, and PET/MRI), are promising tools for the management of prostate cancer particularly for therapeutic implications. When used appropriately, the information from functional radionuclide imaging improves, and sometimes significantly changes, the whole course of the cancer management. In particular, while the localized prostate cancer is considered manageable, there is still significant need for improvement in noninvasive imaging of metastatic prostate cancer.

This course covers the rationale of using functional radionuclide imaging in prostate cancer management and the therapeutic implications for each prostate cancer radionuclide imaging agent.

Credits

Opus Medicus designates this Internet enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement

Opus Medicus is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Tuition Fees

Course: Free
Credits: $42.00

Course Dates

Last Review Date: 15-Jun-2016
Expiration Date: 15-Jun-2019

Objectives

After completing this course, participants will understand:

1. The rationale of using functional radionuclide imaging in prostate cancer management.

2. Advantages of combining radionuclide and structural imaging modalities.

3. Radionuclide imaging agents used for prostate cancer.

4. Therapeutic implications for each of the radionuclide imaging agents

Topics

1. Combined Radionuclide and Structural Imaging Modalities for Prostate Cancer Management

2. Therapeutic Approaches and Radionuclide Imaging for Prostate Cancer Management

3. Radionuclide Imaging Agents for Prostate Cancer

4. Radionuclide Imaging of Prostate Cancer and Therapeutic Implications

5. Imaging Agents Under Development and Therapeutic Implications

Specific topics covered in this AMA PRA Categogy 1 Credit™ online CME course include bone imaging agents (99mTc-MDP/HDP, 18F-NaF), sentinel lymph node imaging agents (99mTc-albumin colloid, 99mTc-sulfur colloid), Prostate-Specific Membrane Antigen (PSMA) targeting agents (111In-capromab pendetide, 177Lu-J591, 123I-MIP-1072), non-prostate-specific metabolic PET imaging agents (18F-fluorodeoxyglucose [FDG], 11C/18F-choline, 11C/18F-acetate), androgen receptor and protein synthesis imaging agents (18F-fluorodihydrotestosterone [FDHT], and 11C-methionine).

American Board of Medical Specialties (ABMS) / Accreditation Council for Graduate Medical Education (ACGME) Competencies

☑  Patient Care (PC)
☑  Medical Knowledge (MK)

Financial Relationship Disclosure and Content Attestation

Dr. Carina Mari Aparici attests that she has no financial relationships with a commercial entity offering healthcare related products and/or services. Dr. Youngho Seo attests that commercial entities with which he has relationships do not offer healthcare related products or services relevant to the content of this course. Dr. Steven R. Tahan, Education Committee Chair, attests that commercial entities with which he has relationships do not offer healthcare related products or services relevant to the content of this course. No other person who has provided content for or who can influence the content of this course has disclosed financial relationships with commercial entities that offer healthcare-related products or services relevant to the course content.

There has been no commercial support for this course.

Supported Computer Hardware and Software Configurations1

Supported client computing platforms include:

A broadband Internet connection is required (e.g., cable, DSL, and 3G or 4G wireless). The course presentation is automatically scaled to the size of the display, from 800x480 pixels (minimum supported) to 1920x1200 pixels. On some smart phones, viewing courses may be tedious.

Supported browsers include:

Javascript, cookies, and popups must be enabled on your browser (which is the default configuration for most browsers).


1. The course may also be viewable on other client computing platforms that comply with Internet standards. If you experience technical problems that prevent you from viewing the course, we will promptly issue a full refund upon request.